rock as a therapeutic target of diabetic retinopathy岩石作为一种治疗糖尿病性视网膜病变的目标.pdf

Hindawi Publishing Corporation Journal of Ophthalmology Volume 2010, Article ID 175163, 9 pages doi:10.1155/2010/175163 Review Article ROCK as a Therapeutic Target of Diabetic Retinopathy Ryoichi Arita, Yasuaki Hata, and Tatsuro Ishibashi Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka 812-8582, Japan Correspondence should be addressed to Yasuaki Hata, hatachan@med.kyushu-u.ac.jp Received 2 December 2009; Accepted 9 April 2010 Academic Editor: Kavita Hegde Copyright © 2010 Ryoichi Arita et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The increasing global prevalence of diabetes is a critical problem for public health. In particular, diabetic retinopathy, a prevalent ocular complication of diabetes mellitus, causes severe vision loss in working population. A better understanding of the pathogenesis and the development of new pharmacologic treatments are needed. This paper describes the relevance between Rho/ROCK pathway and the pathogenesis of diabetic retinopathy from its early to late stages. Moreover, the therapeutic potential of ROCK inhibitor in the total management of diabetic retinopathy is discussed. 1. Introduction intercellular adhesion molecule-1 (ICAM-1), and leukocyte β2 -integrins (CD18/CD11a and CD18/CD11b) [6–8]. In The growing prevalence of diabetic retinopathy (DR), the addition, the critical mechanism of this leukocyte-induced common ocular